Physician profile
Glenn Campbell
NPI 1063429470
$3,594.57
in general payments reported to CMS, 2019-2025
26 companies · $894 in 2025
The $894 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80.63 · 2020: $174 · 2021: $123 · 2022: $313 · 2023: $810 · 2024: $1,200 · 2025: $894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,904.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,903.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $692.23 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $462.52 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $458.87 | 2019-2025 | Farxiga, Airsupra |
| Pfizer INC. | $338.26 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $241.40 | 2024-2025 | Xifaxan |
| Abbott Laboratories | $220.71 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.23 | 2023-2025 | Jardiance |
| Amgen INC. | $146.44 | 2023-2025 | Evenity, Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $125.04 | 2023-2024 | |
| Novo Nordisk INC | $122.78 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $80.11 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $77.20 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $63.61 | 2023-2025 | Gardasil 9, Capvaxive, Gardasil |
| Glaxosmithkline, LLC. | $58.37 | 2022-2024 | Shingrix, Arexvy, Boostrix |
| Takeda Pharmaceuticals U.S.A., INC. | $42.84 | 2020-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $39.17 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.62 | 2024-2025 | |
| Inspire Medical Systems, INC. | $36.20 | 2024-2025 | Inspire |
| Allergan, INC. | $33.00 | 2020 | |
| Sanofi-Aventis U.S. LLC | $32.66 | 2020-2022 | |
| Dynavax Technologies Corporation | $32.64 | 2023-2024 | Heplisav-B |
| Shield Therapeutics INC | $27.90 | 2024 | |
| Phathom Pharmaceuticals, INC. | $20.62 | 2024 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $15.53 | 2022 | |
| Medtronic, INC. | $14.20 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.